, with combined sales of $24.9 billion and a projected 7.3% share of the global pharmaceutical market, the companies said. Glaxo SmithKline will have its corporate headquarters in London with operational headquarters in a new location in the U.S. Glaxo SmithKline expects its shares will be listed on the London and New York stock exchanges.